RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · USHealthcareBiotechnology
$28.53-2.56%
Price as of Jul 20, 2026
RARE growth
Ultragenyx Pharmaceutical Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +13.3%
- EBITDA
- -11.9%
- EBIT
- -9.4%
- EPS
- -3.9%
- Free cash flow
- -18.0%
- Operating cash flow
- -27.3%
Forward estimates
- Revenue
- +26.2%
- EBITDA
- -53.8%
- EPS
- +58.8%
Three-year CAGR
- Revenue
- +22.8%
- EBITDA
- -1.1%
- EBIT
- +0.2%
- Net income
- -1.0%
- EPS
- +7.3%
- Free cash flow
- -11.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.